Login:
 
The Practitioner 2007;251(1690):18-23

PCA3 improves diagnosis of prostate cancer

01 Jan 2007Pais-up subscribers

A single prostate specific antigen (PSA) measurement is of limited use in differentiating between prostate cancer and BPH, unless it is significantly elevated. When the most frequently used PSA cut-off point of 4.0 ng/ml is employed, a significant number of patients with BPH are identified as false positives for prostate cancer. Men with a PSA of between 4.0 and 10.0 ng/ml have around a 20 per cent chance of having prostate cancer; in those with a PSA of >10.0 ng/ml, the chance of a positive biopsy is 62 per cent. However, the recent Prostate Cancer Prevention Trial (PCPT) demonstrated that 17 per cent of men who were identified with prostate cancer in fact had a PSA value below 4.0 ng/ml, and some patients had a value below 2.5 ng/ml. Annual measurement of PSA may improve accurate diagnosis, but is also controversial. [With external links to the evidence base]

Paid-up subscribersThis article can be accessed only if you are a paid-up subscriber to The Practitioner.

To view current online and print subscription rates, and to contact the subscription department, click Subscribe today .

To buy this article (£25+tax) copy the article citation above and click Buy article